Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes |
| |
Authors: | Nehler Mark R,Brass Eric P,Anthony Richard,Dormandy John,Jiao Jenny,McNamara Thomas O,Hiatt William R Circulase investigators |
| |
Affiliation: | University of Colorado Health Sciences Center and the Colorado Prevention Center, Denver, CO 80262-0302, USA. Mark.Nehler@uchsc.edu |
| |
Abstract: | PURPOSE: In patients with critical limb ischemia (CLI), distal revascularization remains the procedure of choice for preventing limb loss, but long-term outcomes for pain relief, wound healing, and prevention of amputation remain suboptimal. Prostaglandin drug therapy as an adjuvant to revascularization may improve these outcomes. The current trial was designed to test the hypothesis that the use of lipo-ecraprost, a lipid encapsulated prostaglandin E(1) prodrug, as an adjunctive therapy after distal revascularization would improve amputation-free survival in patients with CLI. METHODS: The study was randomized, multicenter, double blind, and placebo controlled. Patients meeting clinical and hemodynamic criteria for CLI who were undergoing either bypass or endovascular revascularization of the below knee popliteal or more distal arteries were randomized to receive placebo or a 60-microg dose of lipo-ecraprost administered intravenously starting
|
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|